薬価基準改定が製薬企業の売上高に及ぼす影響について

DOI Web Site

書誌事項

タイトル別名
  • Influences of NHI Price Revision on Sales Figures of Pharmaceutical Companies
  • ヤッカ キジュン カイテイ ガ セイヤク キギョウ ノ ウリアゲダカ ニ オヨボス エイキョウ ニ ツイテ

この論文をさがす

抄録

To investigate the influences of the 2010 revision of medical reimbursement system on the sales figures of the 39 pharmaceutical companies listed on the Japanese stock exchange market, the financial data obtained from EDINET (Electronic Disclosure for Investors’ NETwork) were examined. In April 2010, 5.75% of the standard price of drug prescribed under the Japanese Health Insurance System was reduced, which caused 2.62% reduce of drug costs in the national medical expenditure from 8.01 trillion yen to 7.80 trillion yen. However, there was no decrease in the gross sales of 39 pharmaceutical companies listed in Japanese stock market, and furthermore the sales of four high ranks increased considerably all. The rate of change of drug costs in the national medical expenditure in drug price revision year (1998–2011) was −2.38±4.747 (mean±s.d.)%, which was statistically lower than 5.57±2.741 (mean±s.d.) % of that in non-revision year (P<0.05: Wilcoxon signed-ranks test).

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ